ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,520
similar
All similar
Record
: found
Abstract
: not found
Book
: not found
(erdafitinib) [prescribing information]
Author(s):
Publication date:
2022
Read this book at
Bookmark
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Management Information Systems
Data availability:
Comments
Comment on this book
Sign in to comment
Similar content
1,520
BALVERSA (erdafitinib) tablets, for oral use [prescribing information
Authors:
Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Authors:
S. Tagawa
,
A. Siefker-Radtke
,
A‐G Dosne
…
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
Authors:
Yohann Loriot
,
Andrea Necchi
,
Se Hoon Park
…
See all similar
Cited by
1
HER2 expression in urothelial carcinoma, a systematic literature review
Authors:
Emilie Scherrer
,
Ashley Kang
,
Lisa Bloudek
…
See all cited by